171 related articles for article (PubMed ID: 28222997)
1. Integrated analysis of recombinant BPV-1 L1 protein for the production of a bovine papillomavirus VLP vaccine.
Módolo DG; Araldi RP; Mazzuchelli-de-Souza J; Pereira A; Pimenta DC; Zanphorlin LM; Beçak W; Menossi M; de Cassia Stocco R; de Carvalho RF
Vaccine; 2017 Mar; 35(12):1590-1593. PubMed ID: 28222997
[TBL] [Abstract][Full Text] [Related]
2. Production of immunogenic recombinant L1 protein of bovine papillomavirus type 9 causing teat papillomatosis.
Watanabe S; Shibahara T; Andoh K; Hatama S; Mase M
Arch Virol; 2020 Jun; 165(6):1441-1444. PubMed ID: 32239294
[TBL] [Abstract][Full Text] [Related]
3. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.
Kirnbauer R; Chandrachud LM; O'Neil BW; Wagner ER; Grindlay GJ; Armstrong A; McGarvie GM; Schiller JT; Lowy DR; Campo MS
Virology; 1996 May; 219(1):37-44. PubMed ID: 8623552
[TBL] [Abstract][Full Text] [Related]
4. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
5. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
Bolhassani A; Shirbaghaee Z; Agi E; Davoudi N
Protein Expr Purif; 2015 Dec; 116():7-11. PubMed ID: 26304732
[TBL] [Abstract][Full Text] [Related]
6. Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes.
Shafti-Keramat S; Schellenbacher C; Handisurya A; Christensen N; Reininger B; Brandt S; Kirnbauer R
Virology; 2009 Oct; 393(1):1-6. PubMed ID: 19729180
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.
Schellenbacher C; Huber B; Skoll M; Shafti-Keramat S; Roden RBS; Kirnbauer R
Vaccine; 2019 Jun; 37(27):3529-3534. PubMed ID: 31147274
[TBL] [Abstract][Full Text] [Related]
9. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
[TBL] [Abstract][Full Text] [Related]
10. Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.
Berg MG; Adams RJ; Gambhira R; Siracusa MC; Scott AL; Roden RB; Ketner G
Clin Vaccine Immunol; 2014 Sep; 21(9):1224-31. PubMed ID: 24990902
[TBL] [Abstract][Full Text] [Related]
11. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.
Diamos AG; Larios D; Brown L; Kilbourne J; Kim HS; Saxena D; Palmer KE; Mason HS
Vaccine; 2019 Jan; 37(1):137-144. PubMed ID: 30459071
[TBL] [Abstract][Full Text] [Related]
12. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity.
Pan H; Li Z; Wang J; Song S; Wang D; Wei M; Gu Y; Zhang J; Li S; Xia N
Vaccine; 2017 May; 35(24):3222-3231. PubMed ID: 28483196
[TBL] [Abstract][Full Text] [Related]
13. In planta production of a candidate vaccine against bovine papillomavirus type 1.
Love AJ; Chapman SN; Matic S; Noris E; Lomonossoff GP; Taliansky M
Planta; 2012 Oct; 236(4):1305-13. PubMed ID: 22718313
[TBL] [Abstract][Full Text] [Related]
14. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.
Berg M; Difatta J; Hoiczyk E; Schlegel R; Ketner G
Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4590-5. PubMed ID: 15767581
[TBL] [Abstract][Full Text] [Related]
15. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
16. Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine.
Xu D; Wang D; Yang X; Cao M; Yu J; Wang Y
Antiviral Res; 2014 Feb; 102():61-9. PubMed ID: 24333518
[TBL] [Abstract][Full Text] [Related]
17. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
18. A multimeric L2 vaccine for prevention of animal papillomavirus infections.
Jagu S; Malandro N; Kwak K; Yuan H; Schlegel R; Palmer KE; Huh WK; Campo MS; Roden RB
Virology; 2011 Nov; 420(1):43-50. PubMed ID: 21920572
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies.
Gaukroger JM; Chandrachud LM; O'Neil BW; Grindlay GJ; Knowles G; Campo MS
J Gen Virol; 1996 Jul; 77 ( Pt 7)():1577-83. PubMed ID: 8758002
[TBL] [Abstract][Full Text] [Related]
20. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
